CME: Updates in Hemophilia: Making Headway in the Multidisciplinary Setting

Updates in Hemophilia: Making Headway in the Multidisciplinary Setting

Updates in Hemophilia: Making Headway in the Multidisciplinary Setting
For the 20,000 patients living with hemophilia, there’s hope on the not-so-distant horizon thanks to these emerging treatment options.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Have you considered using replacement factors or gene therapy in your practice to manage hemophilia? This activity explores the most recent clinical trial data and real-world experience of these and other emerging treatment regimens for hemophilia.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Matt Birnholz, MD
    Medical Director
    Ft. Washington, PA

    Dr. Birnholz has nothing to disclose.

    Michael Recht, MD, PhD
    Professor of Pediatrics and Medicine
    Director, The Hemophilia Center
    Oregon Health and Science University
    Portland, OR

    Dr. Recht receives consulting fees from Bioverative, CSL Behring, Genentech, Kedrion, NovoNordisk, Pfizer, Shire, uniQure and has contracted research with Bioverative, Genentech, NovoNordisk, Shire, Spark, uniQure and is on the Board of Directors of ATHN.

    Reviewers/Content Planners/Authors:

    • Christa Dardaganian has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Kim Farina, PhD has disclosed she has ownership interest in Immunomedics Stock.
    • The Postgraduate Institute for Medicine planners and managers have nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients with hemophilia.  After participating in this educational activity, participants should be better able to:

    • Summarize the most current clinical trial data and real-world experience with prophylactic or on-demand treatment regimens
    • Describe the latest evidence regarding emerging options for the management of patients with hemophilia, including replacement factors and gene therapy
  • Target Audience

    This activity is designed to meet the educational needs of hematologists and registered nurses, as well as the other members of the hemophilia treatment team, including pharmacists, physical therapists, and social workers, and other members of the interprofessional team who are involved in the management of patients with hemophilia.  

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Omnia-Prova Education Collaborative (TOPEC). TOPEC is accredited by the ACCME to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Joint Accreditation Statement 


    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The Omnia-Prova Education Collaborative (TOPEC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours. Designated for 0.2 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
    Link to PIM:

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Sanofi Genzyme.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free